Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 2/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13134189 | 0.85 | GRIK1 (0.48) | GRIK1FLT3CYP2A6DRD2NPC1 | |
| SCHEMBL4792534 | 0.83 | GRIK1 (0.46) | GRIK1FLT3CYP2A6DRD2NPC1 | |
| SCHEMBL9269321 | 0.81 | GRIK1 (0.56) | GRIK1FLT3DRD2NPC1LMNA | |
| SCHEMBL31487774 | 0.79 | MTNR1A (0.53) | GRIK1FLT3DRD2NPC1LMNA | |
| SCHEMBL5493171 | 0.79 | KDM4E (0.51) | GRIK1FLT3DRD2NPC1LMNA | |
| SCHEMBL4413986 | 0.79 | MTNR1A (0.53) | GRIK1FLT3DRD2NPC1LMNA | |
| SCHEMBL5515054 | 0.79 | GRIK1 (0.51) | GRIK1FLT3CYP2A6DRD2NPC1 | |
| SCHEMBL4410319 | 0.79 | DRD2 (0.49) | GRIK1FLT3DRD2NPC1LMNA | |
| SCHEMBL34461886 | 0.79 | DRD2 (0.49) | GRIK1FLT3DRD2NPC1LMNA | |
| SCHEMBL13134382 | 0.78 | GRIK1 (0.51) | GRIK1FLT3CYP2A6DRD2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112294798-A | Composition for reducing absorption of lipase inhibitor in digestive tract | 中山万汉制药有限公司 | 2021-02-02 | — | — | CN | claimed |
| CN-112294798-A | Composition for reducing absorption of lipase inhibitor in digestive tract | 中山万汉制药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112294798-A | Composition for reducing absorption of lipase inhibitor in digestive tract | 中山万汉制药有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-112263575-A | Composition containing orlistat and indoxyl acetamide compound and application thereof | 中山万汉制药有限公司 | 2021-01-26 | — | — | CN | disclosed |
| CN-112263575-A | Composition containing orlistat and indoxyl acetamide compound and application thereof | 中山万汉制药有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-9499484-B2 | Indole, indoline derivatives, compositions comprising them and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2016-11-22 | — | — | US | disclosed |
| US-9458161-B1 | TSPO ligands for cancer imaging and treatment | VANDERBLIT UNIVERSITY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2015-03-26 | — | — | US | disclosed |
| EP-2847165-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2015-03-18 | — | — | EP | disclosed |
| WO-2013150529-A2 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2013-10-10 | — | — | WO | disclosed |
| US-8131527-B1 | FGFR pharmacophore compounds | ASTEX THERAPEUTICS LTD. (GB) | 2012-03-06 | — | — | US | disclosed |
| EP-1751161-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | Bristol-Myers Squibb Company (US) | 2007-02-14 | — | — | EP | disclosed |
| EP-1641777-A1 | INDOLE DERIVATIVES WITH APOPTOSIS-INDUCING EFFECT | Zentaris GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005054247-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2004108702-A1 | INDOLE DERIVATIVES WITH APOPTOSIS-INDUCING EFFECT | ZENTARIS GMBH (DE) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087617-A1 | INDOLE, INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF | IDO1, INMT, IDO2 | GRIK1 1346/4885FLT3 1183/4885CYP2A6 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.